| Wastewater treatment and reuse: a review of its applications and health implications KK Kesari, R Soni, QMS Jamal, P Tripathi, JA Lal, NK Jha, MH Siddiqui, ... Water, Air, & Soil Pollution 232, 1-28, 2021 | 223 | 2021 |
| Novel CRISPR–Cas systems: an updated review of the current achievements, applications, and future research perspectives S Nidhi, U Anand, P Oleksak, P Tripathi, JA Lal, G Thomas, K Kuca, ... International journal of molecular sciences 22 (7), 3327, 2021 | 171 | 2021 |
| Decision support systems for personalized and participative radiation oncology P Lambin, J Zindler, BGL Vanneste, L Van De Voorde, D Eekers, ... Advanced drug delivery reviews 109, 131-153, 2017 | 153 | 2017 |
| An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe D Horgan, M Jansen, L Leyens, JA Lal, R Sudbrak, E Hackenitz, ... Public health genomics 17 (5-6), 287-298, 2014 | 109 | 2014 |
| Digitalisation and COVID-19: the perfect storm D Horgan, J Hackett, CB Westphalen, D Kalra, E Richer, M Romao, ... Biomedicine Hub 5 (3), 1-23, 2020 | 64 | 2020 |
| An overview of nanoscale materials on the removal of wastewater contaminants R Soni, AK Pal, P Tripathi, L JA, K Kesari, V Tripathi Applied Water Science 10 (189), 1-9, 2020 | 41 | 2020 |
| Chlamydia trachomatis Infections and Subfertility: Opportunities to Translate Host Pathogen Genomic Data into Public Health JA Lal, J Malogajski, SP Verweij, P De Boer, E Ambrosino, A Brand, ... Public Health Genomics 16 (1-2), 50-61, 2013 | 36 | 2013 |
| European best practice guidelines for quality assurance, provision and use of genome-based information and technologies: the 2012 declaration of Rome A Brand, JA Lal Drug Metabolism and Drug Interactions 27 (3), 177-182, 2012 | 36* | 2012 |
| European health data space—An opportunity now to grasp the future of data-driven healthcare D Horgan, M Hajduch, M Vrana, J Soderberg, N Hughes, MI Omar, JA Lal, ... Healthcare 10 (9), 1629, 2022 | 28 | 2022 |
| Public health and valorization of genome-based technologies: a new model JA Lal, T Schulte in den Bäumen, SA Morré, A Brand Journal of translational medicine 9, 1-15, 2011 | 27* | 2011 |
| Accelerating the development and validation of liquid biopsy for early cancer screening and treatment tailoring D Horgan, T Čufer, F Gatto, I Lugowska, D Verbanac, Â Carvalho, JA Lal, ... Healthcare 10 (9), 1714, 2022 | 20 | 2022 |
| RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases D Taruscio, C Morciano, P Laricchiuta, P Mincarone, F Palazzo, CG Leo, ... Rare Diseases and Orphan Drugs 1 (1), 5-10, 2014 | 14 | 2014 |
| Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective L Leyens, D Horgan, JA Lal, K Steinhausen, K Satyamoorthy, A Brand Personalized Medicine 11 (7), 641-649, 2014 | 13 | 2014 |
| Burden of Chlamydia trachomatis in India: a systematic literature review P Thomas, J Spaargaren, R Kant, R Lawrence, A Dayal, JA Lal, SA Morré Pathogens and Disease 75 (5), 2017 | 11 | 2017 |
| Making the most of innovation in personalised medicine: an EU strategy for a faster bench to bedside and beyond process D Horgan, JA Lal Public Health Genomics 21 (3-4), 101-120, 2019 | 10 | 2019 |
| Sexually transmitted infections and behavioral determinants of sexual and reproductive health in the Allahabad District (India) based on data from the ChlamIndia study PPM Thomas, J Yadav, R Kant, E Ambrosino, S Srivastava, G Batra, ... Microorganisms 7 (11), 557, 2019 | 8 | 2019 |
| Next-generation sequencing: an emerging tool for drug designing P Tripathi, J Singh, JA Lal, V Tripathi Current Pharmaceutical Design 25 (31), 3350-3357, 2019 | 8 | 2019 |
| Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area D Horgan, Y Hamdi, JA Lal, T Nyawira, S Meyer, D Kondji, NM Francisco, ... Healthcare 11 (3), 431, 2023 | 7 | 2023 |
| Methodology for production of best practice guidelines for rare diseases T Sejersen, C Del Giovane, G Filippini, CG Leo, JJ Meerpohl, ... Rare Diseases and Orphan Drugs 1 (1), 2014 | 7 | 2014 |
| The overarching framework of translation and integration into healthcare: a case for the LAL model JA Lal, SA Morre, A Brand Personalized medicine 11 (1), 41-62, 2014 | 7 | 2014 |
